Hemophilia Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Hemophilia Treatment Market Insights and Statistics, and It is Segmented by Disease Type (Hemophilia A, Hemophilia B, and Other Disease Types), Therapy (Replacement Therapy, Gene Therapy, and Other Therapies), Product Type (Recombinant Coagulation Factor Concentrates, Plasma-Derived Coagulation Factor Concentrates, and Other Product Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Size and Forecasts are Provided in Terms of Value (USD) for the Above Segments.

Hemophilia Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Hemophilia Market Size

Hemophilia Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 14.41 Billion
Market Size (2030) USD 18.83 Billion
CAGR (2025 - 2030) 5.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Hemophilia Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Hemophilia Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Hemophilia Market Analysis

The Hemophilia Market size is estimated at USD 14.41 billion in 2025, and is expected to reach USD 18.83 billion by 2030, at a CAGR of 5.5% during the forecast period (2025-2030).

Certain factors driving the market’s growth include the growing prevalence of hemophilia, favorable government initiatives, and rising research and development. For instance, according to the World Federation of Hemophilia Global Report 2022, around 18,580 people were diagnosed with hemophilia in the United States in 2022. Hemophilia is a genetic blood disorder that damages the normal functionality of blood clotting and coagulation. Around 386,966 people with bleeding disorders were identified globally, of which 233,577 cases were hemophilia. Such a huge prevalence of hemophilia globally is expected to lead to increased adoption of therapies, driving market growth.

Additionally, an increase in grants for research on hemophilia is expected to contribute to market growth over the forecast period. For instance, in March 2022, a researcher from the Indiana University School of Medicine received USD 2 million from the National Heart Lung and Blood Institute to develop three major themes in a gene therapy approach that could lead to safer and potentially curative treatments for hemophilia. Such grants may lead to the development of novel therapies for hemophilia, thereby driving market growth over the forecast period.

Similarly, in January 2023, BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, publicized positive results from more than three years of follow-up from its global Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec). It was an investigational one-time gene therapy for treating adults with severe hemophilia A. It was the largest and longest global Phase 3 study for any gene therapy in hemophilia, with 134 participants.

Moreover, rising product approvals from the US Food and Drug Administration are expected to propel market growth. For instance, in March 2022, Freeline Therapeutics Holdings PLC dosed the first patient in its Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for treating hemophilia B. It is a debilitating genetic bleeding disorder caused by a clotting factor IX protein deficiency.

Thus, due to the rise in hemophilia cases and the increase in product launches, coupled with research and development for hemophilia therapies, the market studied is expected to witness significant growth during the forecast period. However, the high cost of hemophilia treatment and the need for more awareness among people regarding advanced technologies are expected to hinder market growth.

Hemophilia Industry Overview

The hemophilia market is semi consolidated in nature and consists of a few major players. The key players are also involved in various strategic alliances such as acquisitions, collaborations, and launching advanced products and research studies to secure their position in the global market. Some of the key market players in this market include Bayer AG, BioMarin, CSL Limited (CSL Behring), Novo Nordisk, Pfizer Inc., Sanofi (Genzyme Corporation), and Takeda Pharmaceutical Company Limited (Shire PLC).

Hemophilia Market Leaders

  1. Pfizer, Inc.

  2. Bayer AG

  3. Novo Nordisk A/S

  4. CSL Limited (CSL Behring)

  5. BioMarin

  6. *Disclaimer: Major Players sorted in no particular order
Hemophilia Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Hemophilia Market News

  • April 2024: The Food and Drug Administration approved Pfizer's Beqvez, a novel gene therapy designed for individuals with the less common "B" form of hemophilia.
  • February 2023: The US Food and Drug Administration approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]. It was previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is the first and only hemophilia A treatment that delivers normal to near-normal factor activity levels (over 40%) for most of the week with once-weekly dosing, significantly reducing bleeds compared to prior factor VIII prophylaxis.

Hemophilia Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumption and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Hemophilia
    • 4.2.2 Favorable Government Initiatives
    • 4.2.3 Rising R&D and New Product Development
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Lack of Awareness Regarding Advanced Technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Disease Type
    • 5.1.1 Hemophilia A
    • 5.1.2 Hemophilia B
    • 5.1.3 Other Disease Types
  • 5.2 By Therapy
    • 5.2.1 Replacement Therapy
    • 5.2.2 Gene Therapy
    • 5.2.3 Other Therapies
  • 5.3 By Product Type
    • 5.3.1 Recombinant Coagulation Factor Concentrates
    • 5.3.2 Plasma-derived Coagulation Factor Concentrates
    • 5.3.3 Other Product Types
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 BioMarin
    • 6.1.3 CSL Limited (CSL Behring)
    • 6.1.4 Kedrion SpA
    • 6.1.5 Novo Nordisk A/S
    • 6.1.6 Pfizer Inc.
    • 6.1.7 F. Hoffmann-La Roche AG (Chugai Pharmaceutical Co.)
    • 6.1.8 Sanofi (Genzyme Corporation)
    • 6.1.9 Takeda Pharmaceutical Company Limited (Shire PLC)
    • 6.1.10 Grifols SA
    • 6.1.11 Medexus Pharmaceuticals Inc.
    • 6.1.12 Octapharma AG
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Hemophilia Industry Segmentation

As per the scope of the report, hemophilia is a genetic bleeding disorder that prevents the blood from clotting normally due to a lack of enough blood-clotting proteins (clotting factors). People with hemophilia contain low levels of either factor VIII (8) or factor IX (9). The primary symptom is uncontrolled, often spontaneous bleeding in different body areas. The amount of bleeding depends on the severity of hemophilia.

The hemophilia market is segmented by disease type, therapy, product type, and geography. By disease type, the market is segmented as hemophilia A, hemophilia B, and other disease types. By therapy, the market is segmented as replacement therapy, gene therapy, and other therapies. By product type, the market is segmented as recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, and other product types. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally and offers the value (USD) for the above segments.

By Disease Type Hemophilia A
Hemophilia B
Other Disease Types
By Therapy Replacement Therapy
Gene Therapy
Other Therapies
By Product Type Recombinant Coagulation Factor Concentrates
Plasma-derived Coagulation Factor Concentrates
Other Product Types
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Hemophilia Market Research FAQs

How big is the Hemophilia Market?

The Hemophilia Market size is expected to reach USD 14.41 billion in 2025 and grow at a CAGR of 5.5% to reach USD 18.83 billion by 2030.

What is the current Hemophilia Market size?

In 2025, the Hemophilia Market size is expected to reach USD 14.41 billion.

Who are the key players in Hemophilia Market?

Pfizer, Inc., Bayer AG, Novo Nordisk A/S, CSL Limited (CSL Behring) and BioMarin are the major companies operating in the Hemophilia Market.

Which is the fastest growing region in Hemophilia Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Hemophilia Market?

In 2025, the North America accounts for the largest market share in Hemophilia Market.

What years does this Hemophilia Market cover, and what was the market size in 2024?

In 2024, the Hemophilia Market size was estimated at USD 13.62 billion. The report covers the Hemophilia Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Hemophilia Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Hemophilia Industry Report

The hemophilia industry is experiencing significant growth, driven by the increasing prevalence of the disorder and heightened awareness of genetic abnormalities. Advances in gene and replacement therapy are introducing innovative treatments, promising better management and potential cures. The industry benefits from robust investments in R&D, leading to novel therapies for hemophilia A and B patients. Supportive government initiatives and specialized treatment centers are enhancing care access and patient outcomes, with the prophylaxis treatment segment leading the market. This shift towards proactive management, coupled with a focus on improving patients' quality of life and reducing treatment frequency, characterizes the industry's evolution. The sector is buoyed by a strong pipeline of gene therapy products and an emphasis on early detection and treatment, signaling a new era of care. According to Mordor Intelligence™ Industry Reports, the market is poised for continued expansion and innovation, with detailed statistics on market share, size, and revenue growth rates available in a free report PDF download, offering a comprehensive forecast outlook and historical overview of the hemophilia market.